Pure Cycle PCYO Ratios & Valuation
| TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 64.8%-1.5pp | 63.2%-5.8pp | 61.5%-7.3pp | 66.4%+6.3pp | 66.3%+4.9pp | |
| Operating margin | 38.9%+1.3pp | 35.1%-6.9pp | 29.4%-13.2pp | 34.7%+11.6pp | 37.6%+10.0pp | |
| Net margin | 45.8%-1.6pp | 46.6%+0.3pp | 50.3%+9.9pp | 49.6%+18.6pp | 47.4%+12.7pp | |
| Returns | ||||||
| Return on equity | 9.9%-1.2pp | 9.8%-0.9pp | 9.6%+0.3pp | 10.5%+5.4pp | 11.1%+5.5pp | |
| Return on invested capital | 6.5%-0.8pp | 6%-2.1pp | 4.8%-3.7pp | 6%+2.7pp | 7.3%+3.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.4×-2.4× | 2.3×-1.3× | 2.7×-1.3× | 3.5×+0.4× | 3.8×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | 0.2×+0.9× | -0.7×+0.1× | -1.5×-0.5× | -0.6×+1.4× | -0.7×+1.1× | |
| Per Share | ||||||
| Book value per share | $6.15+10.7% | $6.11+10.4% | $5.91+9.9% | $5.66+11.0% | $5.56+11.4% | |
| Valuation | ||||||
| Market capitalization | $258.15M+3.7% | $274.04M-21.8% | $243.15M-5.2% | $257.62M+15.0% | $280.01M+16.6% | |
| Price / earnings | 18.6×+0.1× | 19.9×-6.0× | 18.5×-3.5× | 18.9×-18.0× | 19.8×-17.0× | |
| Price / sales | 8.5×-0.7× | 9.3×-2.7× | 9.3×+0.4× | 9.4×-2.1× | 9.4×-3.4× | |
| Price / book | 1.8×-0.1× | 1.9×-0.8× | 1.7×-0.3× | 1.9×+0.1× | 2.1×+0.1× | |
| EV / EBITDA | 18.6×-2.2× | 20.9×-2.7× | 22.9×+6.0× | 21.4×-10.4× | 20×-11.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Pure Cycle's ratios come from?
- Every ratio is computed from Pure Cycle's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.